All Stories

  1. Beyond LDL-C levels, does remnant cholesterol estimation matter?

    Article • European Journal of Preventive Cardiology, February 2020, SAGE Publications

    Professor Alberico L. Catapano

  2. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

    Article • European Heart Journal, August 2019, Oxford University Press (OUP)

    Professor Alberico L. Catapano, Colin Baigent

  3. Statins increase Lp(a) plasma level: is this clinically relevant?

    Article • European Heart Journal, July 2019, Oxford University Press (OUP)

    Professor Alberico L. Catapano, Dr Angela Pirillo

  4. Biological Consequences of Dysfunctional HDL

    Article • Current Medicinal Chemistry, May 2019, Bentham Science Publishers

    Dr Angela Pirillo, Professor Alberico L. Catapano

  5. Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity

    Article • Cardiovascular Research, March 2019, Oxford University Press (OUP)

    Professor Alberico L. Catapano

  6. Novel strategies to target PCSK9: beyond monoclonal antibodies

    Article • Cardiovascular Research, January 2019, Oxford University Press (OUP)

    Professor Alberico L. Catapano, Dr Angela Pirillo

  7. Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: The end of a dream?

    Article • European Journal of Preventive Cardiology, December 2018, SAGE Publications

    Professor Alberico L. Catapano, Dr Angela Pirillo

  8. Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases

    Article • European Heart Journal, October 2017, Oxford University Press (OUP)

    Professor Alberico L. Catapano

  9. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

    Article • Vascular Health and Risk Management, September 2017, Dove Medical Press

    Professor Alberico L. Catapano, Dr Angela Pirillo

  10. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

    Article • European Heart Journal, August 2017, Oxford University Press (OUP)

    Professor Alberico L. Catapano

  11. PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans

    Article • European Journal of Preventive Cardiology, July 2017, SAGE Publications

    Professor Alberico L. Catapano

  12. PCSK9 inhibition in statin-intolerant HeFH patients: What’s new?

    Article • European Journal of Preventive Cardiology, July 2017, SAGE Publications

    Professor Alberico L. Catapano, Dr Angela Pirillo

  13. Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3

    Article • Drug Design Development and Therapy, April 2015, Taylor & Francis

    Professor Alberico L. Catapano, Dr Angela Pirillo

  14. HDL in innate and adaptive immunity

    Article • Cardiovascular Research, June 2014, European Society of Cardiology

    Professor Alberico L. Catapano, Dr Angela Pirillo

  15. Lipoprotein Remnants and Endothelial Dysfunction in the Postprandial Phase

    Article • The Journal of Clinical Endocrinology & Metabolism, June 2004, Endocrine Society

    Professor Alberico L. Catapano